enGene Therapeutics Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2022 | $-17.6M | $-17.7M | $153.0K | $116.0K |
| FY2023 | $-24.7M | $-25.1M | $318.0K | $3.5M |
| FY2024 | $-48.3M | $-49.2M | $925.0K | $5.3M |
| FY2025 | $-99.2M | $-100.7M | $1.5M | $9.6M |